There are 2867 resources available
783TiP - Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS)
Presenter: Alexander Spira
Session: Poster session 14
975P - Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial
Presenter: Egbert Smit
Session: Poster session 14
977P - Phase II study of brigatinib in patients with tyrosine kinase inhibitor (TKI)-naïve ROS1-rearranged advanced non-small cell lung cancer (NSCLC): Barossa cohort 1
Presenter: Ryo Toyozawa
Session: Poster session 14
978P - Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
Presenter: Apar Kishor Ganti
Session: Poster session 14
979P - Long-term intracranial safety and efficacy analyses from the phase III CROWN study
Presenter: Alessandra Bearz
Session: Poster session 14
980P - Continuation of selpercatinib beyond progression in RET fusion-positive NSCLC: Data from LIBRETTO-001 study
Presenter: Alexander Drilon
Session: Poster session 14
981P - A phase IIa study to evaluate safety and efficacy of rezivertinib (BPI-7711) in locally advanced or metastatic/recurrent treatment-naïve NSCLC patients with EGFR mutation
Presenter: Yuan-Kai Shi
Session: Poster session 14
982P - Final results and biomarker analysis of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study
Presenter: Atsushi Nakamura
Session: Poster session 14
984P - Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD)
Presenter: Shirish Gadgeel
Session: Poster session 14